Cover Image
市場調查報告書

中國的醫藥品、醫療產業(季度更新報告)

China Pharmaceuticals and Healthcare Report Q1 2017

出版商 BMI Research 商品編碼 209173
出版日期 內容資訊 英文 152 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的醫藥品、醫療產業(季度更新報告) China Pharmaceuticals and Healthcare Report Q1 2017
出版日期: 2016年11月09日 內容資訊: 英文 152 Pages
簡介

儘管經濟的減速,中國許多外資製藥企業,持續以2位數成長率伸展收益。由於人口的高齡化,個人資產的增加,政府對醫療的輔助策略等要素,預計國外投資家,今後也持續投資中國的醫藥品、醫療產業。

本報告提供中國的製藥、醫療產業結構和最新趨勢相關分析、今後10年的產業規模的動向估計、產業課題(風險)和未來商機(利潤)相關評估、政府的政策、規定、宏觀經濟環境、主要企業簡介等資訊彙整,為您概述為以下內容。

BMI的見解

SWOT分析

  • 政治
  • 經濟
  • 業務營運風險

產業預測

  • 醫藥品市場預測
  • 醫療市場預測
  • 處方藥市場預測
  • 專利藥市場預測
  • 學名藥市場預測
  • 一般用(OTC)醫藥品市場預測
  • 醫藥品的對外貿易預測
  • BMI的預測方案相關主要風險

宏觀經濟預測

  • 經濟活動

產業的風險/利潤、等級

  • 亞太地區:風險/利潤、等級
  • 中國:風險/利潤、等級
    • 利潤
    • 風險

市場概況

產業的趨勢與發展

  • 流行病學
  • 醫療部門
  • 研究開發(R&D)
  • 臨床實驗
  • 生物科技部門

法規的發展

  • 法規的體制
  • 知識產權相關課題
  • 價格決策的體制
  • 醫療費償付的體制

競爭環境

  • 研究開發意向型產業
  • 學名藥廠商
  • 醫藥品的批發業
  • 近幾年趨勢
  • 中藥

企業簡介

  • AstraZeneca
  • Bayer
  • China Shijiazhuang Pharmaceutical Group
  • Eli Lilly
  • GlaxoSmithKline
  • North China Pharmaceutical Corporation
  • Novartis
  • Merck & Co
  • Merck KGaA
  • Pfizer
  • Roche
  • Sanofi
  • Shanghai Pharmaceutical
  • Sinopharm

人口結構的預測

詞彙表

分析方法

  • 醫藥品支出額的預測模式
  • 醫療費的預測模式
  • 分析方法的相關註記
  • 風險/利潤、等級技術
  • 指標概要
  • 指標的加權

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 1748-1821

BMI View:: Multinational drugmakers will face significant challenges in maintaining double-digit revenue growth rates in China. Reforms to the healthcare sector will continue over the coming quarters as authorities seek to expand healthcare access while containing costs in a macro environment that has seen economic growth slow. Provincial nuances will become more pertinent as the economic trajectories of each diverge and bidding processes differ. Collectively, this demands new approaches by multinational drugmakers to the China pharmaceutical market, integrating the macro-economic risk factors with a province level approach.

Headline Expenditure Projections

  • Pharmaceuticals: CNY688bn (USD109bn) in 2015 to CNY766bn (USD115bn) by 2016; +11.5% in local currency terms and +5.4% in USD terms.
  • Healthcare: CNY3,953bn (USD629bn) in 2015 to CNY4,424bn (USD665bn) in 2015; +11.9% in local currency and +5.8% in USD terms.

Risk/Reward Index

In Q117, China is amongst the most attractive countries according to our Pharmaceutical Risk/Reward Index. The country scores 62.6 out of 100 and is ranked sixth amongst 19 other Asia Pacific countries. Key to China's strong score is its high market expenditure, high sector value growth and policy continuity. The only limiting factors come from the country's business transparency and limited legal diligence.

Table of Contents

BMI Industry View

  • Table: Headline Pharmaceuticals & Healthcare Forecasts (China 2014-2020)

SWOT

Industry Forecast

  • Pharmaceutical Market Forecast
    • Table: Pharmaceutical Sales, Historical Data And Forecasts (China 2012-2020)
  • Healthcare Market Forecast
    • Table: Healthcare Expenditure Trends, Historical Data And Forecasts (China 2012-2020)
    • Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (China 2012-2020)
    • Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (China 2012-2020)
  • Prescription Drug Market Forecast
    • Table: Prescription Drug Market Indicators, Historical Data And Forecasts (China 2012-2020)
  • Patented Drug Market Forecast
    • Table: Patented Drug Market Indicators, Historical Data And Forecasts (China 2012-2020)
  • Generic Drug Market Forecast
    • Table: Generic Drug Market Indicators, Historical Data And Forecasts (China 2012-2020)
  • OTC Market Forecast
    • Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (China 2012-2020)
  • Pharmaceutical Trade Forecast
    • Table: Pharmaceutical Trade Data And Forecasts (China 2014-2020)
    • Table: Pharmaceutical Trade Data And Forecasts local currency (China 2014-2020)

Industry Risk/Reward Index

  • Asia Pacific Risk/Reward Index - Q1 2017
  • China Risk/Reward Index
    • Rewards
    • Risks

Regulatory Review

  • Regulatory Regime
    • Table: Important China GMP Deadlines
  • Intellectual Property Issues
    • Table: PhRMA's Special 301 submission, China, 2014-16
  • Pricing Regime
  • Reimbursement Regime
  • China - 13th Five-Year Plan To Reinforce Existing Trends

Market Overview

  • Healthcare Sector
    • Table: Healthcare Resources (China 2010-2015)
    • Table: Healthcare Personnel (China 2010-2015)
    • Table: Healthcare Activity (China 2010-2015)
  • Research & Development
    • Table: Selected List Of MNC With R&D Bases In China
    • Table: Selected List Of Collaboration In R&D Operations In China
  • Clinical Trials
  • Epidemiology
    • Table: Estimated Number Of New Cases Of Cancer In China

Competitive Landscape

  • Research-Based Industry
    • Table: Companies Represented by RDPAC
    • Table: Multinational Market Activity
  • Generic Drugmakers
  • Pharmaceutical Distribution

Company Profile

  • AstraZeneca
  • Bayer
  • China Shijiazhuang Pharmaceutical Group
  • Eli Lilly
  • GlaxoSmithKline
  • North China Pharmaceutical Corporation
  • Novartis
  • Merck & Co
  • Merck KGaA
  • Pfizer
  • Roche
  • Sanofi
  • Shanghai Pharmaceutical
  • Sinopharm

13th Five Year Plan

  • 13th Five-Year Plan: Key Points
    • Summary Of Contents
    • Chapter 1: Overview
      • Table: Targets
    • Chapter 2: Innovation To Drive Development
    • Chapter 3: Economic Institutions
    • Chapter 4: Modernisation Of The Agricultural Sector
    • Chapter 5: Industries
    • Chapter 6: Expand The Network Economy
    • Chapter 7: Build A Modern Infrastructure Network
    • Chapter 8: New-Type Urbanisation
    • Chapter 9: Coordination Of Regional Development
    • Chapter 10: Environmental Protection
    • Chapter 11: Continue Opening Up
    • Others:

Demographic Forecast

  • Table: Population Headline Indicators (China 1990-2025)
  • Table: Key Population Ratios (China 1990-2025)
  • Table: Urban/Rural Population & Life Expectancy (China 1990-2025)
  • Table: Population By Age Group (China 1990-2025)
  • Table: Population By Age Group % (China 1990-2025)

Glossary

Methodology

  • Pharmaceutical Expenditure Forecast Model
  • Healthcare Expenditure Forecast Model
  • Notes On Methodology
  • Risk/Reward Index Methodology
  • Index Overview
    • Table: Pharmaceutical Risk/Reward Index Indicators
  • Indicator Weightings
Back to Top